Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Ueno

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Clinical Ethics|January 1, 1991
Sedation before ventilator withdrawalB S Edwards, W M Ueno
Journal of Biological Response Modifiers|January 1, 1984
Phase II trial of thymosin fraction 5 in advanced renal cancerR S Schulof, M J Lloyd, W M Ueno, et al.
Cancer Treatment Reports|March 1, 1981
CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lungR J Cambareri, F P Smith, J S Macdonald, et al.
Clinical Therapeutics|May 1, 1993
Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patientsJ A Miller, T Butler, R A Beveridge, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapyR A Beveridge, J A Miller, A N Kales, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Ethics|January 1, 1991
Sedation before ventilator withdrawalB S Edwards, W M Ueno
Journal of Biological Response Modifiers|January 1, 1984
Phase II trial of thymosin fraction 5 in advanced renal cancerR S Schulof, M J Lloyd, W M Ueno, et al.
Cancer Treatment Reports|March 1, 1981
CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lungR J Cambareri, F P Smith, J S Macdonald, et al.
Clinical Therapeutics|May 1, 1993
Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patientsJ A Miller, T Butler, R A Beveridge, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapyR A Beveridge, J A Miller, A N Kales, et al.
Pageof 1